Christian S. Schade

CHRISTIAN S. SCHADE has been a director since 2006.

Christian currently serves as a growth partner of Flagship Pioneering, a venture capital company that invests in biotechnology, life sciences, health and sustainability companies.

Prior to joining Flagship, Christian served as the president and chief executive officer of Aprea Therapeutics, a publicly traded, clinical-stage biopharmaceutical company from 2016 to 2022. Prior to joining Aprea Therapeutics, Christian was the chief executive officer of Novira Therapeutics, Inc., an antiviral drug discovery company focused on first-in-class therapeutics for chronic HBV infection, until it was acquired by Johnson & Johnson. Before joining Novira Therapeutics, he served as executive vice president and chief financial officer of Omthera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on the clinical development of therapies for dyslipidemia. Previous to this role, Christian assumed a variety of senior leadership roles, including serving as executive vice president and chief financial officer at NRG Energy, senior vice president for administration and chief financial officer at Medarex Inc., and as managing director at Merrill Lynch, leading the European Corporate Funding Group. He also held various corporate finance and capital markets roles in New York and London for both Merrill Lynch and JP Morgan Chase & Co.

Currently, Christian serves as Board Chair for Omega Therapeutics (Nasdaq: OMGA), Alltrna Therapeutics, Ring Therapeutics, and Valo Health.

Christian received an A.B. degree from Princeton University and received an MBA from the Wharton School at the University of Pennsylvania.